BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 36213111)

  • 61. A systematic analysis of
    Jiang Y; Wang X; Li L; He J; Jin Q; Long D; Liu C; Zhou W; Liu K
    Front Genet; 2022; 13():926943. PubMed ID: 35991552
    [No Abstract]   [Full Text] [Related]  

  • 62. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
    Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
    Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pan-cancer analyses confirmed the cuproptosis-related gene FDX1 as an immunotherapy predictor and prognostic biomarker.
    Zhang C; Zeng Y; Guo X; Shen H; Zhang J; Wang K; Ji M; Huang S
    Front Genet; 2022; 13():923737. PubMed ID: 35991547
    [No Abstract]   [Full Text] [Related]  

  • 64. Analysis of prognostic genes in the tumor microenvironment of lung adenocarcinoma.
    Xu ZY; Zhao M; Chen W; Li K; Qin F; Xiang WW; Sun Y; Wei J; Yuan LQ; Li SK; Lin SH
    PeerJ; 2020; 8():e9530. PubMed ID: 32775050
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
    Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
    Front Genet; 2022; 13():919389. PubMed ID: 35783281
    [No Abstract]   [Full Text] [Related]  

  • 66. An integrated pan-cancer analysis of PSAT1: A potential biomarker for survival and immunotherapy.
    Feng M; Cui H; Tu W; Li L; Gao Y; Chen L; Li D; Chen X; Xu F; Zhou C; Cao Y
    Front Genet; 2022; 13():975381. PubMed ID: 36105075
    [TBL] [Abstract][Full Text] [Related]  

  • 67. CD93 Correlates With Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis.
    Zhang Z; Zheng M; Ding Q; Liu M
    Front Cell Dev Biol; 2022; 10():817965. PubMed ID: 35242761
    [No Abstract]   [Full Text] [Related]  

  • 68. Integrated analysis and validation reveal ACAP1 as a novel prognostic biomarker associated with tumor immunity in lung adenocarcinoma.
    Wang N; Zhu L; Xu X; Yu C; Huang X
    Comput Struct Biotechnol J; 2022; 20():4390-4401. PubMed ID: 36051873
    [TBL] [Abstract][Full Text] [Related]  

  • 69. CD1B is a Potential Prognostic Biomarker Associated with Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Adenocarcinoma.
    Li Z; Feng Y; Li P; Wang S; Liu X; Xia S
    Int J Gen Med; 2022; 15():3809-3826. PubMed ID: 35418778
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Significance of Tumor Mutation Burden in Immune Infiltration and Prognosis in Cutaneous Melanoma.
    Kang K; Xie F; Mao J; Bai Y; Wang X
    Front Oncol; 2020; 10():573141. PubMed ID: 33072607
    [No Abstract]   [Full Text] [Related]  

  • 71. Effect of TTN Mutations on Immune Microenvironment and Efficacy of Immunotherapy in Lung Adenocarcinoma Patients.
    Wang Z; Wang C; Lin S; Yu X
    Front Oncol; 2021; 11():725292. PubMed ID: 34513703
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The value of
    Feng Y; Wang Y; Guo K; Feng J; Shao C; Pan M; Ding P; Liu H; Duan H; Lu D; Wang Z; Zhang Y; Zhang Y; Han J; Li X; Yan X
    Ann Transl Med; 2022 Apr; 10(8):466. PubMed ID: 35571400
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A pan-cancer analysis of FAT atypical cadherin 4 (FAT4) in human tumors.
    Mao W; Zhou J; Hu J; Zhao K; Fu Z; Wang J; Mao K
    Front Public Health; 2022; 10():969070. PubMed ID: 36051999
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Immune checkpoint PTPN2 predicts prognosis and immunotherapy response in human cancers.
    Tang X; Sui X; Liu Y
    Heliyon; 2023 Jan; 9(1):e12873. PubMed ID: 36685446
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prognostic value and immunological role of cathepsin S gene in pan‑cancer.
    Liang S; Dang B; Chen S; Mi H
    Oncol Lett; 2024 Jan; 27(1):41. PubMed ID: 38108072
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Decreased expression of HADH is related to poor prognosis and immune infiltration in kidney renal clear cell carcinoma.
    Jiang H; Chen H; Wan P; Chen N
    Genomics; 2021 Nov; 113(6):3556-3564. PubMed ID: 34391866
    [TBL] [Abstract][Full Text] [Related]  

  • 77. N6AMT1 is a novel potential diagnostic, prognostic and immunotherapy response biomarker in pan-cancer.
    Wang M; Zhu J; Ye Y; Li P; Sun W; Zhang M
    Aging (Albany NY); 2023 Jul; 15(13):6526-6544. PubMed ID: 37437243
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The molecular feature of macrophages in tumor immune microenvironment of glioma patients.
    Zhang H; Luo YB; Wu W; Zhang L; Wang Z; Dai Z; Feng S; Cao H; Cheng Q; Liu Z
    Comput Struct Biotechnol J; 2021; 19():4603-4618. PubMed ID: 34471502
    [TBL] [Abstract][Full Text] [Related]  

  • 79. ARPC2: A Pan-Cancer Prognostic and Immunological Biomarker That Promotes Hepatocellular Carcinoma Cell Proliferation and Invasion.
    Huang S; Dong C; Li D; Xu Y; Wu J
    Front Cell Dev Biol; 2022; 10():896080. PubMed ID: 35733852
    [No Abstract]   [Full Text] [Related]  

  • 80. A Pan-Cancer Analysis Revealing the Dual Roles of Lysine (K)-Specific Demethylase 6B in Tumorigenesis and Immunity.
    Ding JT; Yu XT; He JH; Chen DZ; Guo F
    Front Genet; 2022; 13():912003. PubMed ID: 35783266
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.